65 results
DRS/A
EX-10.9
KPRX
Kiora Pharmaceuticals Inc
8 Jul 14
Draft registration statement (amended)
12:00am
Termination
If your Service terminates for any reason except death or total and permanent disability, then this option, to the extent vested … as of your termination date, will expire at the close of business at Company headquarters on the date three months after your termination date.
Death
If you
DRS/A
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
8 Jul 14
Draft registration statement (amended)
12:00am
and may provide for expiration prior to the end of its term in the event of the termination of the Optionee’s Service.
5.5 Death of Optionee. After … an Optionee’s death, any vested and exercisable Options held by such Optionee may be exercised by his or her beneficiary or beneficiaries. Each Optionee
DRS/A
EX-10.10
slghy38rivsdv7sj
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-99.1
i7fr014aqer4 hi
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
EX-10.1
hez08so8 72f
24 Mar 20
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.3
zsn5d1z42 7ga9
1 Feb 21
Departure of Directors or Certain Officers
6:55am
DRS/A
EX-3.3
gixnf
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-3.1
cwxe7v2m
20 Feb 15
Amendments to Articles of Incorporation or Bylaws
12:00am
DRS/A
EX-3.4
fjg 1jnvmazt82
8 Jul 14
Draft registration statement (amended)
12:00am
DRS/A
EX-10.3
0c60yu2
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-3.2
8vkpsae riat7
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-3.1
kohtcg
4 Aug 22
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-10.1
b6g2b3vmt4oo gb0hd05
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-3.2
8agn9rga9shga61y
20 Feb 15
Amendments to Articles of Incorporation or Bylaws
12:00am